Axsome Therapeutics (AXSM) Gains from Investment Securities (2015 - 2018)
Axsome Therapeutics (AXSM) posted Gains from Investment Securities of -$102000.0 for Q4 2018, down 580.0% sequentially from -$15000.0 in Q3 2018.
Powered by 
Analysis
Axsome Therapeutics (AXSM) Gains from Investment Securities (2015 - 2018) Analysis & Trends
Axsome Therapeutics has reported Gains from Investment Securities for 2 years, with the latest figure at -$102000.0 in Q4 2018.
- Quarterly Gains from Investment Securities changed N/A year-over-year to -$102000.0 in Q4 2018, while the trailing twelve-month figure through Dec 2018 was -$2.8 million (changed N/A YoY) and the FY2018 annual result came in at -$2.8 million, down 532.04% from the prior year.
- Gains from Investment Securities declined to -$102000.0 in Q4 2018 per AXSM's latest filing, from -$15000.0 in the prior quarter.
- Over five years, Gains from Investment Securities peaked at $93976.0 in Q4 2015 and troughed at -$2.7 million in Q1 2018.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Axsome Therapeutics | 10.75 Bn | 10.43 Bn | 204.81 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2018 | -102,000.00 |
| Sep 30, 2018 | -15,000.00 |
| Jun 30, 2018 | -1,000.00 |
| Mar 31, 2018 | -2.67 Mn |
| Dec 31, 2015 | 93,976.00 |
| Sep 30, 2015 | 32,005.00 |
| Jun 30, 2015 | -16,572.00 |
| Mar 31, 2015 | -870.00 |